In this paper, Bayesian decision procedures are developed for dose-escalation studies based on bivariate observations of undesirable events and signs of therapeutic benefit. The methods generalize earlier approaches taking into account only the undesirable outcomes. Logistic regression models are used to model the two responses, which are both assumed to take a binary form. A prior distribution for the unknown model parameters is suggested and an optional safety constraint can be included. Gain functions to be maximized are formulated in terms of accurate estimation of the limits of a 'therapeutic window' or optimal treatment of the next cohort of subjects, although the approach could be applied to achieve any of a wide variety of objectives. The designs introduced are illustrated through simulation and retrospective implementation to a completed dose-escalation study.

Download full-text PDF

Source
http://dx.doi.org/10.1002/sim.2201DOI Listing

Publication Analysis

Top Keywords

bayesian decision
8
decision procedures
8
undesirable events
8
therapeutic benefit
8
procedures dose-escalation
4
dose-escalation based
4
based evidence
4
evidence undesirable
4
events therapeutic
4
benefit paper
4

Similar Publications

Correction: Decision-Making, Pro-variance Biases and Mood-Related Traits.

Comput Psychiatr

January 2025

Max Planck University College London Centre for Computational Psychiatry and Ageing Research, University College London, London WC1B 5EH, United Kingdom.

[This corrects the article DOI: 10.5334/cpsy.114.

View Article and Find Full Text PDF

Despite similar incidence rates, nationwide breast cancer mortality is 40% higher among non-Hispanic Black (NHB) than non-Hispanic White (NHW) women. The racial disparity persists even among women with early-stage disease, prognostically favorable subtypes, and indicators of high socioeconomic status and is not evenly distributed throughout the US. Understanding geographic differences may provide additional insight into the drivers of the disparity.

View Article and Find Full Text PDF

There is growing consensus in the Alzheimer's community that combination therapy will be needed to maximize therapeutic benefits through the course of the disease. However, combination therapy raises complex questions and decisions for study sponsors, from preclinical research through clinical trial design to regulatory, statistical, and operational considerations. In January 2024, the Alzheimer's Drug Discovery Foundation convened an expert advisory board to discuss the key considerations in each of these areas.

View Article and Find Full Text PDF

The kinetically-derived maximal dose (KMD) is defined as the maximum external dose at which kinetics are unchanged relative to lower doses, e.g., doses at which kinetic processes are not saturated.

View Article and Find Full Text PDF

Bayesian network for predicting mandibular third molar extraction difficulty.

BMC Oral Health

January 2025

Sub-Institute of Public Safety Standardization, China National Institute of Standardization, No.4 Zhichun Road, Haidian District, Beijing, 100191, PR China.

Background: This study aimed to establish a model for predicting the difficulty of mandibular third molar extraction based on a Bayesian network to meet following requirements: (1) analyse the interaction of the primary risk factors; (2) output quantitative difficulty-evaluation results based on the patient's personal situation; and (3) identify key surgical points and propose surgical protocols to decrease complications.

Methods: Relevant articles were searched to identify risk factors. Clinical knowledge and experience were used to analyse the risk factors to establish the Bayesian network.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!